Patents by Inventor Nigel P. Shankley

Nigel P. Shankley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRHR2 peptide agonists and uses thereof
    Patent number: 10040838
    Abstract: The present invention relates to novel peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists and compositions thereof for the treatment, amelioration or inhibition of cardiovascular conditions, including but not limited to heart failure. The novel peptide agonist preferably comprise modifications that include pegylated peptides. Furthermore, the present invention also relates to methods for the treatment and prevention of a disease or disorder related to CRHR2 activity.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: August 7, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Ronald V. Swanson, Nigel P. Shankley, Veronica Moreno, Peter Gengo
  • METHOD FOR TREATING HEART FAILURE WITH STRESSCOPIN-LIKE PEPTIDES
    Publication number: 20110105397
    Abstract: The present invention relates to novel methods of treating heart failure comprising administering an amount of stresscopin-like peptide to a subject in need thereof; and substantially maintaining the amount of said peptide present in the plasma of said subject at a concentration resulting in a therapeutic benefit without a substantial increase in the heart rate of said subject. The method involves the use of stresscopin-like peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists.
    Type: Application
    Filed: November 4, 2010
    Publication date: May 5, 2011
    Inventors: Peter J. Gengo, Hani N. Sabbah, Nigel P. Shankley
  • CRHR2 PEPTIDE AGONISTS AND USES THEREOF
    Publication number: 20100130424
    Abstract: The present invention relates to novel peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists and compositions thereof for the treatment, amelioration or inhibition of cardiovascular conditions, including but not limited to heart failure. The novel peptide agonist preferably comprise modifications that include pegylated peptides. Furthermore, the present invention also relates to methods for the treatment and prevention of a disease or disorder related to CRHR2 activity.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 27, 2010
    Inventors: RONALD V. SWANSON, NIGEL P. SHANKLEY, VERONICA MORENO, PETER GENGO
  • Benzo[1,2,5]thiadiazole compounds
    Patent number: 7550492
    Abstract: Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: June 23, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Brett Allison, Laura C. McAfee, Victor K. Phuong, Michael H. Rabinowitz, Nigel P. Shankley
  • CCK-1 receptor modulators
    Patent number: 7465808
    Abstract: There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.
    Type: Grant
    Filed: September 19, 2005
    Date of Patent: December 16, 2008
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Terrance D. Barrett, J. Guy Breitenbucher, Laurent Gomez, Michael D. Hack, Liming Huang, Kelly J. McClure, Magda F. Morton, Clark A. Sehon, Nigel P. Shankley
  • Canine Cholecystokinin 1 Receptor Materials And Their Use
    Publication number: 20080124741
    Abstract: Canine CCK1 receptor materials are described, such as polypeptides having amino acid sequences corresponding to SEQ ID Nos.: 14, 15, and 16 or functional variants thereof and polynucleotides expressing them having nucleic acid sequences corresponding to SEQ ID Nos.: 11, 12, and 13 or complements thereof. Such materials are useful as reagents in drug screening assays to identify compounds having CCK1R-modulating activity.
    Type: Application
    Filed: October 11, 2005
    Publication date: May 29, 2008
    Inventors: Heng Dai, Magda F. Morton, Jayashree Pyati, Nigel P. Shankley
  • Benzo[1,2,5]thiadiazole compounds
    Patent number: 7241759
    Abstract: Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: July 10, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Brett Allison, Laura C. McAtee, Victor K. Phuong, Michael H. Rabinowitz, Nigel P. Shankley
  • CCK-1 receptor modulators
    Patent number: 7037931
    Abstract: There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: May 2, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Terrance D. Barrett, J. Guy Breitenbucher, Laurent Gomez, Michael D. Hack, Liming Huang, Kelly J. McClure, Magda F. Morton, Clark A. Sehon, Nigel P. Shankley
  • Benzo[1,2,5]thiadiazole compounds
    Publication number: 20040224983
    Abstract: Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.
    Type: Application
    Filed: March 26, 2004
    Publication date: November 11, 2004
    Inventors: Brett Allison, Laura C. McAtee, Victor K. Phuong, Michael H. Rabinowitz, Nigel P. Shankley
  • CCK-1 receptor modulators
    Publication number: 20040067983
    Abstract: There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.
    Type: Application
    Filed: July 2, 2003
    Publication date: April 8, 2004
    Inventors: Terrance D. Barrett, J. Guy Breitenbucher, Laurent Gomez, Michael D. Hack, Liming Huang, Kelly J. McClure, Magda F. Morton, Clark A. Sehon, Nigel P. Shankley
  • Bicyclo 2,2,2!octane derivatives
    Patent number: 5514683
    Abstract: The compounds of the formula I ##STR1## and their pharmaceutical acceptable salts, which are defined herein, are ligands for cholecystokinin and/or gastrin receptors.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: May 7, 1996
    Assignee: James Black Foundation Limited
    Inventors: Sarkis B. Kalindjian, Caroline M. R. Low, Iain M. McDonald, Robert A. D. Hull, Nigel P. Shankley, Ildiko M. Buck, Katherine I. M. Steel, Jonathan M. R. Davies, David J. Dunstone, Elaine A. Harper, Michael J. Pether, Michael J. Bodkin, Matthew J. Tozer, Martin L. Hudson
  • Tetrapeptide derivatives and analogues
    Patent number: 5486597
    Abstract: The C-terminal tetrapeptide of gastrin, Trp-Met-Asp-Phe-NH.sub.2, possesses gastrin pharmacological activity. Replacement of the methionyl moiety in the gastrin tetrapeptide, or its analogs, with a naphthylalanyl group produces compounds which interact with gastrin and/or cholecystokinin receptors, but have reduced gastrin and/or cholecystokinin agonist activity. Such partial agonists or antagonists of gastrin and/or cholecystokinin provide useful therapeutic agents.
    Type: Grant
    Filed: June 17, 1993
    Date of Patent: January 23, 1996
    Assignee: James Black Foundation Limited
    Inventors: Sarkis B. Kalindjian, Howard B. Broughton, Caroline M. R. Low, Iain M. McDonald, Robert A. D. Hull, Nigel P. Shankley, Ildiko M. Buck, Katherine I. M. Steel, Jonathan M. R. Davies
  • Derivatives of aspartic acid and glutamic acid having anticholecystokinin activity
    Patent number: 5399748
    Abstract: Arylsulfonamide derivatives of .alpha.-amino dicarboxylic acids such as aspartic acid and glutamic acid posses anti-cholecystokinin activity. They are useful in the treatment of cholecystokinin-related disorders such as anorexia nervosa, pancreatic inflammation, biliary tract disease, Zollinger-Ellison syndrome and various psychiatric disorders, as well as in the potentiation of opiate analgesia, and in the treatment of certain cancers.
    Type: Grant
    Filed: January 12, 1993
    Date of Patent: March 21, 1995
    Assignee: James Black Foundation Limited
    Inventors: Howard B. Broughton, Sarkis B. Kalindjian, Caroline M. R. Low, Iain M. McDonald, Robert A. D. Hull, Nigel P. Shankley